RR 3, Box 384
THE NUTRI-SPEC LETTER
Guy R. Schenker, D.C.
Your Diphasic Nutrition Plan will build around each patient a protective fortress that will last a lifetime. The benefits to your patients are felt symptomatically almost immediately, and, not only the quality but the length of life is enhanced. Your patients feel better, live longer, and get the most for their nutrition dollars. Meanwhile, you get the satisfaction and the well deserved income from offering a nutrition regimen that is not only satisfying and profitable, but easy to administer.
You already have at your disposal the information you need to pass along to your patients to convince them that estrogen and calcium channel blockers are certain to have a devastating (and even dangerous) impact on health. You also have the protocol to responsibly get your patients off these medications. If you have not received the several issue series of these Letters that explains the damaging effect of the catabolic stress hormone estrogen, along with the way to help your patients withdraw from it with minimal symptoms, then contact us immediately. Likewise, if you did not copy the last page of last month’s Letter explaining, and giving the references supporting, the severe consequences of taking calcium channel blockers, let us know and we will get it to you right away.
You must have these available as handouts to distribute to your patients on these drugs. Nothing you do for these patients will have the lasting benefit you have come to expect from NUTRI-SPEC as long as they continue to take these drugs.
This month’s Letter will be devoted to educating you (and your patients) on the SSRI family of antidepressant drugs.
The story on SSRI’s is a fascinating example of pharmaceutical industry propaganda. Here is the story in a nutshell:
SSRI’s are purported to work by increasing the level of serotonin in the brain. It is true that these drugs do increase serotonin, and it is also true that these drugs do relieve symptoms of depression in a select patient population. However, what you are about to learn, is that the sometimes beneficial symptomatic response that SSRIs produce on depressed patients has absolutely nothing to do with the fact that they raise serotonin levels.
When these drugs first came out I could not believe the story as told by the pharmaceutical companies. Through years of studying biochemistry I’d come across serotonin again and again and again as a metabolite that was active in stress reactions but that was almost entirely damaging --- contributing to platelet aggregation and all sorts of other damaging sequlae of the inflammatory process. When I heard that a class of drugs was being promoted that were beneficial because they raised the levels of this damaging chemical, I was incredulous.
As I read all the literature, the truth gradually became apparent. SSRI’s raise not only serotonin levels they also potentate the activity of epinephrine, norepinepherine, and in some cases dopamine. These are neuro-active substances that are part of the catecholamine family.
As you know from your study of NUTRI-SPEC, there are certain metabolic imbalances (anaerobic, parasympathetic, and ketogenic) that are incapable of producing an adequate stress response with catecholamines. These patients are the ones that respond favorably to SSRIs but they pay a high price. Serotonin has a devastating effect on these patients --- but --- the symptomatic benefit they feel from the increase in catecholamines out- weighs the damaging effect of the increased serotonin.
In those patients that are not anaerobic, parasympathetic or ketogenic, the SSRIs generally do not produce a favorable symptomatic response, and in many cases cause terribly unpleasant side effects. In these patients, obviously, there is no benefit to increasing the catecholamine levels, and the damage from the serotonin has full impact.
On the following pages are important facts regarding serotonin and all the medications that potentiate serotonin (including 5HTP, St. John’s Wort, and tryptophan supplements). The last two of these pages are references from the scientific literature from which I took the information. Please photocopy these pages and use these just like your estrogen and calcium channel blocker information to distribute to your patients.
You must get your patients off these damaging drugs.
Regarding the Medications Prozac and the Other SSRI Drugs:
Role of serotonin in memory impairment. Buhot, Martin, and Segu. Ann Med 2000 Apr;32(3):210-21.
Rapid communication: Whole blood serotonin and the type A behavior pattern. Madsen, and McGuire. Psychosom Med 1984 Nov-Dec;46(6):546-8.
In vivo serotonin release and learned helplessness. Kramer, et al. Psychiatry Res 1994 Jun;52(3):285-93.
Tryptophan metabolism in children with Attention Deficit Disorder. Irwin, et al. Am J. Psychiatry 1981 Aug;138(8):1082-5.
Autistic children and their first-degree relatives: Relationships between serotonin and norepinepherine levels and intelligence. Cook, et al. Neuro-Psychiatry Clin Neurosci 1990 Summer; 2(3):268-74.
Serotonin-induced decrease in brain ATP, stimulation of brain anaerobic glycolysis. Koren-Schwartzer, et al. Gen Pharmacol 1994 Oct; 25(6):1257-1262.
Serotonin-induced swelling of rat liver mitochondria. Watanabe, et al. Endocrinologia Japonica, 1969 Feb, 16(1):133-47.
The influence of serotonin on oxidative metabolism of brain mitochondria. Mahler, and Humoller. Proceedings of the Society for Experimental Biology and Medicine, 1968 Apr, 127(4):1074-9.
Prevention of stress-induced morphological and cognitive consequences. McEwen, et al. Eur Neuropsychopharmacol 1997, Oct;7 Suppl 3:S323-S328.
Platelet secretory products may contribute to neuronal injury. Joseph, et al. Stroke 1991 Nov;22(11):1448-51.
Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. Miller, et al. J Clin Pyschopharmacol 1991 Aug; 11(4):277-9.
Duration and distribution of experimentational muscle hyperalgsia in humans following combined infusions of serotonin and bradykinin. Babenko, et al. Brain Research 2000 Jan 24;853(2):275-81.
Neuroendocrine and substrate responses to altered brain 5-ht activity during prolonged exercise to fatigue. Bailey, et al. J Appl Physiol 1993 Jun; 74(6):3006-12.
Amino Acids and central fatigue. Blomstrand. Amino acids 2001; 20(1):25-34.
Tryptophan availability: relation to elevated brain serotonin in developmentally protein-malnourished rats. Miller, et al. Exp Neurol 1977 Oct; 57(1):142-57.
Low tryptophan diets delay reproductive aging. Segall, et al. Mech Ageing Dev 1983 Nov-Dec;23(3-4):245-52.
Sex, migraine and serotonin interrelationships. Sicuteri, et al. Monogr Neural Sci 1976;3;94-101.
A proposed pathological model in the hippocampus of subjects with schizophrenia. Scarr, et al. Clin Exp Pharmacol Physiol 2001 Jan;28(1-2):70-3.
The effect of serotonergic blockade in preeclamptic patients. Montenegro, et al. Am J Obstet Gynecol 1985 Sep 15;153(2):130-4.
Serotonin and melatonin regulate the release of insulin-like growth factor-I, oxytocin and progesterone. Schaeffer & Sirotkin. Exp Clin Endocrinol Diabetes, 1997, 105:2, 109-12.
Inhibitory role of brain stem serotoninergic neuron system on thyroid function. Ruzsas, et al. Endocrinol Exp 1979 Mar;13(1):9-18.
Diurnal and seasonal variations of melatonin and serotonin in women with seasonal affective disorder. Danilenko, et al. Arctic Med Res 1994 Jul;53(3):137-45.